JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB43037

Recombinant HIV1 p24 protein

Be the first to review this product! Submit a review

|

(10 Publications)

Recombinant HIV1 p24 protein is a HIV-1 M:B_HXB2R Full Length protein, expressed in Escherichia coli, with >95% purity and suitable for ELISA and western blot. The predicted molecular weight of ab43037 protein is 25.6 kDa.

- Save time and ensure accurate results - use our HIV1 p24 as a control

View Alternative Names

Gag-Pol polyprotein, Pr160Gag-Pol, gag-pol, Gag polyprotein, Pr55Gag, gag

1 Images
SDS-PAGE - Recombinant HIV1 p24 protein (AB43037)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant HIV1 p24 protein (AB43037)

Key facts

Purity

>95% SDS-PAGE

Expression system

Escherichia coli

Tags

Tag free

Applications

ELISA, WB

applications

Biologically active

No

Accession

P04585

Animal free

No

Carrier free

No

Species

HIV-1 M:B_HXB2R

Storage buffer

pH: 8.5 Constituents: 48% Urea, 0.605% Tris

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>Excellent antigen for detection of HIV seroconvertors with minimal specificity problems. Immunoreactive with all sera of HIV-1 infected individuals.</p>" } } }

Product details

Ensure the validity of your result using our recombinant HIV-1 p24 core antigen protein ab43037 as a positive control in western blot and SDS-PAGE.

Analyze your HIV-1 p24 ELISA data using the ab43037 protein to generate and plot a standard curve.

ab43037 is immunoreactive with all sera of HIV-1 infected individuals.


Check out our protein gel staining guide for SDS-PAGE here

Check out of western blot protocol for more information here

Check out our ELISA protocol for more information here.

Sequence info

[{"sequence":"PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPAHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPSSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVL","proteinLength":"Full Length","predictedMolecularWeight":"25.58 kDa","actualMolecularWeight":null,"aminoAcidEnd":0,"aminoAcidStart":0,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"P05888","tags":[]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

HIV1 p24 also known as HIV p24 protein is a core protein of the Human Immunodeficiency Virus type 1 (HIV-1). The p24 protein has a molecular weight of about 24 kDa. HIV1 p24 comprises part of the viral capsid which encases the viral RNA genome. This protein is prominently expressed during the early stages of HIV infection. The presence of HIV1 p24 is commonly detected through various laboratory techniques including the use of p24 ELISA kits.
Biological function summary

HIV1 p24 plays an important role in the viral life cycle. It assists in the formation and stability of the viral capsid which is critical for maintaining the integrity of the viral core. HIV p24 is not a lone actor; it is part of the structural framework and interacts with other viral proteins to facilitate the viral assembly and maturation processes. The detection of HIV1 p24 is a marker for viral replication and infection stage.

Pathways

The function of HIV1 p24 aligns significantly within the HIV replication pathway and the host's immune response pathway. HIV p24 is intrinsically tied to processes of viral assembly alongside proteins like Gag and Pol coordinating to ensure successful viral replication. Furthermore the immune system recognizes the HIV1 p24 protein thereby integrating it into the host immune response which is important in disease progression and for diagnostic purposes like in the HIV ELISA assay.

HIV1 p24 is integrally connected to HIV/AIDS a disorder that profoundly affects the immune system. The presence of HIV p24 in the bloodstream is an early marker of infection and is frequently monitored to track the disease's progression. Alterations in the levels of p24 protein relate to the efficiency of therapeutic interventions. The study of HIV1 p24 also brings focus on its interaction with the CD4 receptor which is pivotal in the viral entry process further linking various stages of the HIV infection cycle to potential therapeutic targets.

Specifications

Form

Liquid

Additional notes

Organic extraction > S-Sepharose > S-300.

General info

Function

Gag-Pol polyprotein. Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.. Matrix protein p17. Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus (By similarity). Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA (By similarity).. Capsid protein p24. Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion (PubMed : 8648689). Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (PubMed : 12660176). Host restriction factors such as monkey TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species (PubMed : 23785198). Host PIN1 apparently facilitates the virion uncoating (By similarity). On the other hand, interactions with PDZD8 or CYPA stabilize the capsid (PubMed : 24554657).. Nucleocapsid protein p7. Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates in gRNA dimerization, packaging, tRNA incorporation and virion assembly.. Protease. Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane (PubMed : 11932404, PubMed : 9573231). Cleavages take place as an ordered, step-wise cascade to yield mature proteins (PubMed : 11932404, PubMed : 9573231). This process is called maturation (PubMed : 11932404, PubMed : 9573231). Displays maximal activity during the budding process just prior to particle release from the cell (PubMed : 11932404, PubMed : 9573231). Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles (PubMed : 7835426). Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (PubMed : 12660176, PubMed : 19914170). Also mediates cleavage of host YTHDF3 (PubMed : 32053707). Mediates cleavage of host CARD8, thereby activating the CARD8 inflammasome, leading to the clearance of latent HIV-1 in patient CD4(+) T-cells after viral reactivation; in contrast, HIV-1 can evade CARD8-sensing when its protease remains inactive in infected cells prior to viral budding (PubMed : 33542150).. Reverse transcriptase/ribonuclease H. Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.. Integrase. Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.

Post-translational modifications

Gag-Pol polyprotein. Specific enzymatic cleavages by the viral protease yield mature proteins. The protease is released by autocatalytic cleavage. The polyprotein is cleaved during and after budding, this process is termed maturation. Proteolytic cleavage of p66 RT removes the RNase H domain to yield the p51 RT subunit. Nucleocapsid protein p7 might be further cleaved after virus entry.. Matrix protein p17. Tyrosine phosphorylated presumably in the virion by a host kinase. Phosphorylation is apparently not a major regulator of membrane association (PubMed:17656588).. Capsid protein p24. Phosphorylated possibly by host MAPK1; this phosphorylation is necessary for Pin1-mediated virion uncoating.. Nucleocapsid protein p7. Methylated by host PRMT6, impairing its function by reducing RNA annealing and the initiation of reverse transcription.

Product protocols

Target data

Gag-Pol polyprotein. Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.. Matrix protein p17. Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus (By similarity). Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA (By similarity).. Capsid protein p24. Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion (PubMed : 8648689). Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (PubMed : 12660176). Host restriction factors such as monkey TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species (PubMed : 23785198). Host PIN1 apparently facilitates the virion uncoating (By similarity). On the other hand, interactions with PDZD8 or CYPA stabilize the capsid (PubMed : 24554657).. Nucleocapsid protein p7. Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates in gRNA dimerization, packaging, tRNA incorporation and virion assembly.. Protease. Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane (PubMed : 11932404, PubMed : 9573231). Cleavages take place as an ordered, step-wise cascade to yield mature proteins (PubMed : 11932404, PubMed : 9573231). This process is called maturation (PubMed : 11932404, PubMed : 9573231). Displays maximal activity during the budding process just prior to particle release from the cell (PubMed : 11932404, PubMed : 9573231). Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles (PubMed : 7835426). Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (PubMed : 12660176, PubMed : 19914170). Also mediates cleavage of host YTHDF3 (PubMed : 32053707). Mediates cleavage of host CARD8, thereby activating the CARD8 inflammasome, leading to the clearance of latent HIV-1 in patient CD4(+) T-cells after viral reactivation; in contrast, HIV-1 can evade CARD8-sensing when its protease remains inactive in infected cells prior to viral budding (PubMed : 33542150).. Reverse transcriptase/ribonuclease H. Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.. Integrase. Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.
See full target information gag-pol

Additional targets

gag

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 16:813 PubMed39827271

2025

α-Synuclein fibrils enhance HIV-1 infection of human T cells, macrophages and microglia.

Applications

Unspecified application

Species

Unspecified reactive species

Lia-Raluca Olari,Sichen Liu,Franziska Arnold,Julia Kühlwein,Marta Gil Miró,Ajeet Rijal Updahaya,Christina Stürzel,Dietmar Rudolf Thal,Paul Walther,Konstantin M J Sparrer,Karin M Danzer,Jan Münch,Frank Kirchhoff

Npj viruses 2:55 PubMed39553825

2024

Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants.

Applications

Unspecified application

Species

Unspecified reactive species

Michael S Piepenbrink,Ahmed Magdy Khalil,Ana Chang,Ahmed Mostafa,Madhubanti Basu,Sanghita Sarkar,Simran Panjwani,Yaelyn H Ha,Yao Ma,Chengjin Ye,Qian Wang,Todd J Green,James L Kizziah,Nathaniel B Erdmann,Paul A Goepfert,Lihong Liu,David D Ho,Luis Martinez-Sobrido,Mark R Walter,James J Kobie

Cellular and molecular life sciences : CMLS 81:409 PubMed39289189

2024

A naturally occurring 22-amino acid fragment of human hemoglobin A inhibits autophagy and HIV-1.

Applications

Unspecified application

Species

Unspecified reactive species

Dennis Freisem,Armando A Rodriguez-Alfonso,Jan Lawrenz,Zhixuan Zhou,Thomas Monecke,Nico Preising,Sascha Endres,Sebastian Wiese,Ludger Ständker,Seah-Ling Kuan,Dietmar R Thal,Tanja Weil,Dierk Niessing,Holger Barth,Frank Kirchhoff,Mirja Harms,Jan Münch,Konstantin M J Sparrer

Nature communications 15:3813 PubMed38714682

2024

Replication competent HIV-guided CRISPR screen identifies antiviral factors including targets of the accessory protein Nef.

Applications

Unspecified application

Species

Unspecified reactive species

Caterina Prelli Bozzo,Alexandre Laliberté,Aurora De Luna,Chiara Pastorio,Kerstin Regensburger,Stefan Krebs,Alexander Graf,Helmut Blum,Meta Volcic,Konstantin M J Sparrer,Frank Kirchhoff

mBio 15:e0167223 PubMed38193662

2024

SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity.

Applications

Unspecified application

Species

Unspecified reactive species

Fengwen Zhang,Fabian Schmidt,Frauke Muecksch,Zijun Wang,Anna Gazumyan,Michel C Nussenzweig,Christian Gaebler,Marina Caskey,Theodora Hatziioannou,Paul D Bieniasz

Travel medicine and infectious disease 57:102681 PubMed38141899

2023

Evaluation of the accuracy of a multi-infection screening test based on a multiplex immunoassay targeting imported diseases common in migrant populations.

Applications

Unspecified application

Species

Unspecified reactive species

Ruth Aguilar,Angeline Cruz,Alfons Jiménez,Alex Almuedo,Carme Roca Saumell,Marina Gigante Lopez,Oriol Gasch,Gemma Falcó,Ana Jiménez-Lozano,Angela Martínez-Perez,Consol Sanchez-Collado,Andrea Tedesco,Manuel Carlos López,María Jesús Pinazo,Thais Leonel,Zeno Bisoffi,Anna Färnert,Carlota Dobaño,Ana Requena-Méndez

Frontiers in neuroscience 16:906651 PubMed35784841

2022

A Non-Canonical Role for IRE1α Links ER and Mitochondria as Key Regulators of Astrocyte Dysfunction: Implications in Methamphetamine use and HIV-Associated Neurocognitive Disorders.

Applications

Unspecified application

Species

Unspecified reactive species

Jessica Proulx,Satomi Stacy,In-Woo Park,Kathleen Borgmann

Bio-protocol 4: PubMed27525295

2014

Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24.

Applications

Unspecified application

Species

Unspecified reactive species

Marianne Gesner,Mekhala Maiti,Robert Grant,Marielle Cavrois

The Journal of biological chemistry 290:529-43 PubMed25371202

2014

Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.

Applications

Unspecified application

Species

Unspecified reactive species

Arangassery Rosemary Bastian,Aakansha Nangarlia,Lauren D Bailey,Andrew Holmes,R Venkat Kalyana Sundaram,Charles Ang,Diogo R M Moreira,Kevin Freedman,Caitlin Duffy,Mark Contarino,Cameron Abrams,Michael Root,Irwin Chaiken

Proceedings of the National Academy of Sciences of 109:21450-5 PubMed23223527

2012

Microfluidic Western blotting.

Applications

SDS-PAGE

Species

Unspecified reactive species

Alex J Hughes,Amy E Herr
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com